Challenges and Opportunities in Cancer Drug Resistance

• Published in: Chemical reviews Vol. 121; no. 6; pp. 3297 - 3351
• Main Authors: Ward, Richard A, Fawell, Stephen, Floc’h, Nicolas, Flemington, Vikki, McKerrecher, Darren, Smith, Paul D
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 24.03.2021
• Subjects: Blood-brain barrier; Cancer; Drug resistance; Monoclonal antibodies; Scientists; Selectivity
• ISSN: 0009-2665; 1520-6890
• DOI: 10.1021/acs.chemrev.0c00383

There has been huge progress in the discovery of targeted cancer therapies in recent years. However, even for the most successful and impactful cancer drugs which have been approved, both innate and acquired mechanisms of resistance are commonplace. These emerging mechanisms of resistance have been studied intensively, which has enabled drug discovery scientists to learn how it may be possible to overcome such resistance in subsequent generations of treatments. In some cases, novel drug candidates have been able to supersede previously approved agents; in other cases they have been used sequentially or in combinations with existing treatments. This review summarizes the current field in terms of the challenges and opportunities that cancer resistance presents to drug discovery scientists, with a focus on small molecule therapeutics. As part of this review, common themes and approaches have been identified which have been utilized to successfully target emerging mechanisms of resistance. This includes the increase in target potency and selectivity, alternative chemical scaffolds, change of mechanism of action (covalents, PROTACs), increases in blood–brain barrier permeability (BBBP), and the targeting of allosteric pockets. Finally, wider approaches are covered such as monoclonal antibodies (mAbs), bispecific antibodies, antibody drug conjugates (ADCs), and combination therapies.